Immunotherapy

Papers
(The TQCC of Immunotherapy is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Musculoskeletal immune-related adverse events of PD-(L)1 inhibitors in melanoma: a systematic review and meta-analysis70
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)65
From natural defenders to therapeutic warriors: NK cells in HIV immunotherapy61
Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publication49
Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe40
Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database39
Combining in Situ Vaccination and Immunogenic Apoptosis to Treat Cancer38
Systemic Immune–Inflammation Index Predicts Prognosis of Cancer Immunotherapy: Systemic Review and Meta-Analysis36
Volume Increase of Spleen in Melanoma Patients Undergoing Immune Checkpoint Blockade32
Immunotherapeutic Approach for Advanced Pancreatic Adenocarcinoma30
Immune Checkpoint Inhibitor-Induced Myocarditis, Myositis, Myasthenia Gravis and Transaminitis: A Case Series and Review27
Association Between PD-L1 Inhibitor, Tumor Site and Adverse Events of Potential Immune Etiology Within the US FDA Adverse Event Reporting System27
Serplulimab monotherapy in extensive-stage small-cell lung cancer with brain metastasis: a case report27
Venous Thromboembolism Events in Patients with Advanced Cancer on Immune Checkpoint Inhibitors26
Tackling the Immunotherapy Conundrum: Advances and Challenges for Operable Non-Small-Cell Lung Cancer Treatment24
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma23
Boosting the Abscopal Effect with Chemoradiotherapy/Immunotherapy Combination in Metastatic Cervical Cancer: A Case Report22
Efficacy and Safety of Pembrolizumab Combined with Albumin-Bound Paclitaxel and Nedaplatin for Advanced Esophageal Squamous Cell Carcinoma20
Gene Signatures with Therapeutic Value: Emerging Perspective for Personalized Immunotherapy in Renal Cancer20
Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma18
Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events17
CT-P13 Subcutaneous Infliximab in Gastroenterology and Rheumatology16
Immune Checkpoint Inhibitors in Follicular Dendritic Cell Sarcoma16
Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease16
Intratumoral Delivery of Immune Therapy and Gene Therapy: The Next Era for Cancer Therapy15
Cost–Effectiveness Analysis of Nivolumab Plus Cabozantinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma15
What Role will Ensifentrine Play in the Future Treatment of Chronic Obstructive Pulmonary Disease Patients? Implications from Recent Clinical Trials15
B Cells and Their Rolexs in Shaping the Immune Response in Squamous Cell Carcinoma of the Head and Neck14
Gastrointestinal Treatment-Related Adverse Events of Combined Immune Checkpoint Inhibitors: A Meta-Analysis13
Immune checkpoint inhibitors in gynecological cancers: a narrative review on the practice-changing trials13
Development of Hepatitis Triggered by SARS-CoV-2 Vaccination in Patient with Cancer During Immunotherapy: A Case Report13
The Dilemma of Neoadjuvant and Adjuvant Therapy in Urothelial Carcinoma: will Immunotherapy Solve the Problem?13
Toripalimab and Anlotinib as a Maintenance Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report13
Safe Anti-Programmed Cell Death-1 Rechallenge With Antibody Switching After Immune-Related Adverse Events: Brief Communication12
Lichenoid Dermatitis Following Pd-1 Inhibitor-Induced Toxic Epidermal Necrolysis: A Case Report and Literature Review12
Takotsubo Syndrome in a Patient with Metastatic Renal Cell Carcinoma Treated with Pembrolizumab Plus Axitinib12
Clinical Course and Management of Pembrolizumab-Associated Isolated Adrenocorticotrophic Hormone Deficiency: A New Case and Literature Review12
Immune Cells and Signatures Characterize Tumor Microenvironment and Predict Outcome in Ovarian and Endometrial Cancers12
Keeping it Real: Implications of Real-World Treatment Outcomes for First-Line Immunotherapy in Metastatic Non-Small-Cell Lung Cancer11
A Case Report of Pulmonary Nocardiosis During Pembrolizumab: The Emerging Challenge of the Infections on Immunotherapy11
Long-Term Response to Camrelizumab in a Pretreated Metastatic Mixed Testicular Germ-Cell Tumor Patient with Co-Mutations in DNA Damage-Repair Genes11
Fatal Toxicity Induced by anti-PD-1 Immune Checkpoint Inhibitor in Thymic Epithelial Tumor10
Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation10
Lights and Shadows on the Role of Rhg-CSF in Cancer Patients During the COVID-19 Pandemic and Future Perspectives of Research10
Combined Response of Advanced Cutaneous Squamous Cell Carcinoma and Renal Cell Carcinoma to Immunotherapy: A Case Report10
Alemtuzumab-Induced Red Cell Aplasia And Other Immune Cytopenias: Not So €˜Pure’10
Nimotuzumab for COVID-19: Case Series10
Health and Economic Impact of Subcutaneous Allergen Immunotherapy in Patients with Pollen-Induced Allergic Rhinoconjunctivitis: Real-Word Evidence from the Czech Republic9
Successful Treatment with Carboplatin and Paclitaxel in Melanoma Progression After Immune-Related Adverse Events9
Clinical Outcomes of Immune Checkpoint Inhibitor Diabetes Mellitus at a Comprehensive Cancer Center9
Severe Pseudomembranous Keratoconjunctivitis with Deterioration of Eyesight Induced by Immune Checkpoint Inhibitors9
Indications and Effects of Biological Agents in the Treatment of Noninfectious Uveitis9
Combination of Methotrexate with Oral Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Systematic Review9
Neoadjuvant Immunotherapy Plus Chemotherapy and Adjuvant Targeted Therapy in ALK -Positive Non-Small-Cell Lung Cancer9
An Abscopal Effect in a Gastric Cancer Patient Treated with Combined Chemoimmunotherapy and Palliative Radiotherapy9
Real-world Maintenance Therapy and Survival Outcomes For Pembrolizumab Plus Pemetrexed and Platinum for Non-Small-Cell Lung Cancer in USA9
Management of Immune-Mediated Toxicities and their Implications in the Outcomes of Advanced Kidney Cancer9
An Update on the Adalimumab Biosimilar Landscape Following Approval of the First High-Concentration Biosimilar8
The role of ixekizumab in the treatment of nonradiographic axial spondyloarthritis8
Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatment8
Association Between Sex and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta Analysis8
Ocular Toxicities in Chimeric Antigen Receptor T-Cell Therapy: A Real-World Study Leveraging FAERS Database8
Metastatic Gastric Cancer: Synergizing and Sequencing Targeted Therapy with First-Line Immunotherapy8
Is it time to revisit the significance of PD-L1 expression in assisting our treatment decisions?8
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy8
Durable Response After Immune Checkpoint Inhibitor-Related Diabetes in Mismatch Repair-Deficient Pancreatic Cancer8
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab8
Tezepelumab for the Treatment of Severe Asthma: A Plain Language Summary of the PATHWAY and NAVIGATOR Studies8
Are Immune Checkpoint Inhibitors Safe and Effective in Lung Cancer Patients with Pre-Existing Interstitial Lung Disease?8
Deterioration in multifocal motor neuropathy upon treatment of immune-related adverse events of checkpoint inhibition8
Pembrolizumab in an HIV-infected patient with glioblastoma8
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study8
Immune Checkpoint Inhibitors for Advanced or Metastatic Basal Cell Carcinoma: How much Evidence do we Need?8
Case reports of immune-related cystitis and the antibody combination hypothesis7
Chimeric Antigen Receptor Macrophage for Glioblastoma Immunotherapy: The Way Forward7
The Future of Immunotherapy in Advanced Renal Cell Carcinoma: Beyond PD-1/PD-L1 Inhibitors7
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma7
Atezolizumab in Advanced Hepatocellular Carcinoma: Good Things Come to Those Who Wait7
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study7
Development of A Novel Shared Decision Making Aid for Primary Immunodeficiency Diseases7
Peripheral B-cell Levels Predict Efficacy and Overall Survival in Advanced Melanoma Patients Under PD-1 Immunotherapy7
Simultaneous Inhibition of PD-1 and LAG-3: the Future of Immunotherapy?7
Tislelizumab-induced cytokine release syndrome: the first case report and review of the literature7
Herpes Zoster in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors7
Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China7
Tocilizumab in Grade 4 Hepatitis Secondary to Immune Checkpoint Inhibitor: A Case Report and Review of the Literature6
Immunotherapy in Hematological Malignancies: Recent Advances and Open Questions6
Plain language summary of the SHAMAL study in patients with severe eosinophilic asthma treated with benralizumab6
Advancing Immunotherapy in Gastroesophageal Cancer Through Rational Combinations and Biomarkers6
Enteric Plexus Neuropathy Associated with PD-L1 Blockade in a Patient with Small-Cell Lung Cancer6
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia6
Pembrolizumab-Associated Erythema Nodosum in the Treatment of Metastatic Melanoma6
Immunotherapy Versus Standard Chemotherapy For Treatment of Extensive-Stage Small-Cell Lung Cancer: A Systematic Review6
Secukinumab in the Treatment of Hidradenitis Suppurativa6
Encouraging co-targeting of immunoregulatory molecules in cancer treatment6
Could senescent cells be the prescription for therapeutic cancer vaccines?6
Fatal Cytokine-Release Syndrome in A Patient Receiving Toripalimab: A Case Report6
Real-world Study of Hepatic Artery Infusion Chemotherapy Combined With Anti-PD-1 Immunotherapy and Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma6
Toxic Epidermal Necrolysis Associated with Chemoimmunotherapy For Lymphoma: Case Report and Literature Review6
Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patients6
ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis6
Safety levels of systemic IL-12 induced by cDNA expression as a cancer therapeutic6
Fatal rhabdomyolysis and fulminant myocarditis with malignant arrhythmias after one dose of ipilimumab and nivolumab6
Postvaccination immune-mediated hepatitis: what do we really know?6
Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis6
Effect of Sublingual Immunotherapy on Clinical and Laboratory Autoimmunity6
Immunotherapies for prevention and treatment of type 1 diabetes6
Satisfaction, Qol and adherence of patients allergic to dust mites and/or pollens undergoing sublingual immunotherapy6
Successful replacement for recurrent nasopharyngeal carcinoma with cholecystitis induced by PD-1 antibody: a case report6
Safety of Subcutaneous and Sublingual Immunotherapy with Allergoids in Children: A Real-Life Pharmacovigilance Study5
Mesenchymal Stem Cells Derived from Human Dental Follicle Modulate the Aberrant Immune Response in Atopic Dermatitis5
Anti-PD-1 and Regorafenib Induce Severe Multisystem Adverse Events in Microsatellite Stability Metastatic Colorectal Cancer: A Case Report5
Health-related Quality of Life in Patients with Melanoma Brain Metastases Treated with Immunotherapy5
Capillary-Leak Syndrome: An Unrecognized Early Immune Adverse Effect of Checkpoint-Inhibitors Treatment5
Immunotherapy for Gastric Cancer: A 2021 Update5
Adjuvant ArtinM favored the host immunity against Cryptococcus gattii infection in C57BL/6 mice5
Anti-PD-1 Treatment-Induced Immediate Central Diabetes Insipidus: A Case Report5
Comparative Effectiveness of First-Line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors According to IMDC Risk Groups in Metastatic Renal Cell Carcinoma: A Meta-Analysis5
Pathological Findings Directing Immunotherapy in Renal Cell Carcinomas5
Urothelial Carcinoma in The Era of Immune Checkpoint Inhibitors5
Immunotherapy with γδ T-cells: the future is there5
Selection of allergen extract for immunotherapy in polysensitized allergic rhinitis patients5
Update on Immunotherapy in the Management of Gallbladder Cancer5
Comparing Bacillus Calmette-GuéRin (Bcg) Strains in Convalescent Covid-19 Patients5
Pretreatment Lung Immune Prognostic Index as a Biomarker in Advanced Non-Small-Cell Lung Cancer Patients Receiving First Line Pembrolizumab5
A Review of Phase Iii Clinical Trials of Us Fda-Approved Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyposis5
Harnessing Gene Fusion-Derived Neoantigens for ‘Cold’ Breast and Prostate Tumor Immunotherapy5
Determinants of Treatment for First-Line Immune-Based Combinations in Metastatic Renal Cell Carcinoma: a Critical Overview of Recent Evidence5
Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study5
Unraveling the Nexus: Oncogenic Drivers and Immunotherapy Efficacy in Cancer Treatment5
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group)5
Use of Upadacitinib in the Treatment of Psoriatic Arthritis5
Durable Response after Immunotherapy Discontinuation for Delayed and Severe Immune-related Adverse Event: A Case Report5
Safety and Effectiveness of the 300 IR Sublingual House Dust Mite Allergen Immunotherapy Tablet: 2-Year Interim Analysis of a Specified Drug-Use Survey5
Immunoregulatory Effects of Dental Mesenchymal Stem Cells on T and B Lymphocyte Responses in Primary Sjögren's Syndrome5
0.1399929523468